Business Context and Reporting Period
This Form 8-K Current Report was filed by Signal Genetics, Inc. on July 23, 2014, reporting events occurring on July 21, 2014. The filing addresses significant changes in executive leadership, specifically the resignation of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and related contractual agreements.
Material Changes
- Resignation of CFO: Robert Johnson submitted his resignation as Chief Financial Officer, effective August 4, 2014.
- Appointment of New CFO: Tamara A. Seymour was appointed as the new Chief Financial Officer, effective August 4, 2014. Ms. Seymour is a CPA with prior experience as CFO at HemaQuest Pharmaceuticals, Inc. and Favrille, Inc.
- CEO Agreement Amendment: The Chief Executive Officer's employment agreement was amended on July 23, 2014, to ensure compliance with Section 409A of the Internal Revenue Code.
Compensation and Outlook
The filing details the compensation package for the new CFO, Tamara A. Seymour, under an employment agreement effective August 4, 2014:
- Base Salary: $350,000 annually.
- Annual Bonus: Eligible for up to 30% of base salary.
- Equity: 92,000 shares of common stock subject to an equity-based incentive award.
- Term: Initial term through August 4, 2015, with automatic one-year renewals.
- Benefits: Four weeks paid vacation and eligibility for standard senior executive group benefit plans.
The filing includes a press release regarding these changes but does not provide specific forward-looking guidance, risk factors, or management commentary beyond the announcement of the personnel transitions.
Investor Verification Checklist
- Verify the effective date of the CFO transition (August 4, 2014) to assess potential interim financial reporting gaps.
- Review the full text of the Employment Agreement (Exhibit 10.1) for termination clauses and vesting schedules of the 92,000 shares.
- Confirm the impact of the CEO's Section 409A amendment (Exhibit 10.2) on executive compensation timing.
- Check subsequent filings for any financial updates or strategic shifts resulting from the leadership change.